loading page

A NOVEL GERMLINE TP53 MUTATION IN A PATIENT WITH LI-FRAUMENI SYNDROME - RESOLVING A VARIANT OF UNCERTAIN SIGNIFICANCE
  • David Douglass,
  • Kimo Stine,
  • Jason Farrar
David Douglass
University of Arkansas for Medical Sciences
Author Profile
Kimo Stine
University of Arkansas for Medical Sciences
Author Profile
Jason Farrar
University of Arkansas for Medical Sciences
Author Profile

Abstract

Increasing availability of genomic testing poses new challenges to clinicians, particularly where variant interpretation from commercial sources may be equivocal. We report a patient with recurrent rhabdomyosarcoma and subsequent bilateral breast cancer who was found to harbor a previously undescribed germline TP53 sequence alteration annotated by the commercial laboratory as a variant of uncertain significance (VUS). By investigating publically available databases of aggregated normal germline and malignant somatic genomic sequences, we conclude that this missense variant, c.476C>T (p.A159V), is a novel, pathogenic Li-Fraumeni syndrome mutation, and illustrate the utility of these resources in clinical pediatric hematology and oncology practice.